ZHAOKE OPHTH-B - VOLUNTARY ANNOUNCEMENT - REGISTRATION APPLICATION FOR ATROPINE SULFATE EYE DROPS (0.02 STRENGTH) ACCEPTED FOR EVALUATION BY AUSTRALIAS THERAPEUTIC GOODS ADMINISTRATION

Zhaoke Ophthalmology Limited

兆科眼科有限公司

(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)

(Stock Code: 6622)

REGISTRATION APPLICATION FOR

ATROPINE SULFATE EYE DROPS (0.02% STRENGTH)

ACCEPTED FOR EVALUATION BY

AUSTRALIA'S THERAPEUTIC GOODS ADMINISTRATION

This announcement is made by the board of directors (the "Board") of Zhaoke Ophthalmology Limited (the "Company") on a voluntary basis.

The Board of the Company is pleased to announce that, on June 2, 2026, the Company's registration application for its Atropine Sulfate Eye Drops (0.02% strength, product code: NVK002), for the treatment to slow the progression of myopia in children, has been accepted for evaluation by the Therapeutic Goods Administration (the "TGA") of Australia.

The TGA has formally acknowledged that the Company's application has passed a preliminary assessment and will proceed to evaluation. This application is based on positive data from the Phase III clinical trial conducted by the Company.

ABOUT ATROPINE SULFATE EYE DROPS (NVK002)

Atropine Sulfate Eye Drops (NVK002) are eye drops indicated for slowing myopia progression in children and adolescents. Atropine Sulfate Eye Drops (NVK002) adopts a proprietary formulation that effectively resolves the instability of low-concentration atropine. This technology is protected by intellectual property rights globally. The eye drops are preservative-free with a 24-month shelf life.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of

Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately develop, or commercialize Atropine Sulfate Eye Drops successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

Zhaoke Ophthalmology Limited Dr. Li Xiaoyi

Chairman

Hong Kong, June 15, 2026

As at date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.